The levels of disease activity after 6 months of tumor necrosis factor-α inhibitors could help predict the response to therapy at 4 years for those who have long-standing rheumatoid arthritis.
A patent cliff refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Between now and 2030, the biopharma sector is expected to be rocked by a number of high profile patent cliffs that are likely to reshape the market.
A “patent cliff” refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Various types of regulatory exclusivity can occasionally lengthen.